21-Valent Pneumococcal Conjugate Vaccine

Therapeutic Area: ¦

21-Valent Pneumococcal Conjugate Vaccine

21-Valent Pneumococcal Conjugate Vaccine

We are conducting a clinical trial to evaluate the 21-valent pneumococcal conjugate vaccine (PCV21), designed to protect against more strains of Streptococcus pneumoniae than current vaccines. Participants receive access to the investigational vaccine and comprehensive study-related care at no cost, while helping advance research that could strengthen community protection against serious pneumococcal disease.

Therapeutic Area:

Severe Atopic Dermatitis

Severe Atopic Dermatitis

We are conducting a clinical trial for children ages 2–11 living with severe atopic dermatitis. Families who participate receive comprehensive, study-related care at no cost, compensation for time and travel, while contributing to research that may bring relief and hope to children worldwide.